BSE Live
Dec 24, 16:01Prev. Close
5593.95
Open Price
5575.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 24, 15:57Prev. Close
5597.00
Open Price
5570.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Alkem Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | |
| 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||
| Revenue From Operations [Gross] | 1,362.60 | 1,184.87 | 1,023.78 | |
| Less: Excise/Sevice Tax/Other Levies | 18.68 | 23.58 | 47.85 | |
| Revenue From Operations [Net] | 1,343.92 | 1,161.29 | 975.93 | |
| Total Operating Revenues | 1,343.92 | 1,161.29 | 975.93 | |
| Other Income | 78.41 | 59.70 | 47.78 | |
| Total Revenue | 1,422.33 | 1,220.99 | 1,023.72 | |
| EXPENSES | ||||
| Cost Of Materials Consumed | 467.65 | 486.13 | 412.71 | |
| Purchase Of Stock-In Trade | 0.00 | 130.60 | 123.94 | |
| Operating And Direct Expenses | 29.76 | 12.64 | 14.12 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 176.37 | 3.36 | -17.10 | |
| Employee Benefit Expenses | 180.53 | 133.92 | 107.01 | |
| Finance Costs | 20.40 | 14.74 | 15.01 | |
| Depreciation And Amortisation Expenses | 21.06 | 20.84 | 20.01 | |
| Other Expenses | 281.49 | 249.03 | 209.51 | |
| Total Expenses | 1,177.26 | 1,051.24 | 885.20 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 245.07 | 169.75 | 138.52 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 245.07 | 169.75 | 138.52 | |
| Tax Expenses-Continued Operations | ||||
| Current Tax | 11.79 | 0.69 | 2.10 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -1.77 | 6.07 | 5.10 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 7.00 | 10.76 | 10.95 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 238.07 | 158.99 | 127.57 | |
| Profit/Loss From Continuing Operations | 238.07 | 155.80 | 145.07 | |
| Profit/Loss For The Period | 238.07 | 155.80 | 145.07 | |
| OTHER ADDITIONAL INFORMATION | ||||
| EARNINGS PER SHARE | ||||
| Basic EPS (Rs.) | 199.11 | 130.30 | 121.33 | |
| Diluted EPS (Rs.) | 199.11 | 130.30 | 121.33 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||
| Imported Raw Materials | 27.47 | 29.51 | 27.96 | |
| Indigenous Raw Materials | 292.72 | 281.48 | 243.70 | |
| STORES, SPARES AND LOOSE TOOLS | ||||
| Imported Stores And Spares | 0.41 | 0.57 | 0.09 | |
| Indigenous Stores And Spares | 16.20 | 10.11 | 6.17 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||
| Equity Share Dividend | 14.95 | 0.00 | 0.00 | |
| Tax On Dividend | 2.54 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 125.00 | 0.00 | 0.00 |
04.12.2025
Alkem Lab Consolidated September 2025 Net Sales at Rs 4,000.99 crore, up 17.17% Y-o-Y
24.11.2025
Alkem Lab Standalone September 2025 Net Sales at Rs 2,542.03 crore, down 11.49% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key